Bio-Sourcing and Zerion Pharma have obtained a €1.3 million EU grant reward under the Eurostars program to advance an orally administered anti‑HER2 antibody Trastuzimab, for treatment of breast cancer. https://t.co/vtddOHcWQe
Full-Life Technologies announces US$77 million financing to accelerate the development of its radiopharmaceutical pipeline worldwide and manufacturing capabilities in Belgium. https://t.co/X8I2cbybW9
KiOmed Pharma’s innovative osteoarthritis solution, KioMedine-vs-one, has officially been approved by the Chinese FDA, bringing treatment to 100 million patients. https://t.co/9nSVz6mNdV
Hyloris Partners with Kuvatris Therapeutics to Advance Suramin IV Development for Sleeping Sickness, Targeting a Priority Review Voucher. https://t.co/pk36yA9Bwx
Novadip Biosciences received RMAT designation for NVD003, its regenerative treatment for congenital pseudarthosis of the tibia. https://t.co/04ncZrOi8l
ATB Therapeutics Announces Appointment of Dr. Torsten Dreier as Chief Development Officer and Opening of New R&D Hub in Gent. https://t.co/lLeMFwh6WK
For the first time in Belgium, two patients suffering from sarcomas, rare cancers that affect bone or soft tissue, have undergone surgery using augmented reality. https://t.co/t16XKURXEW
Rystiggo (rozanolixizumab) receives approval in Japan for two new administration methods as UCB begins ONWARD program for patient support. https://t.co/1QeoBq6GjB
Do you have an innovative idea in health and need the right partners to bring it to life? If your project fits within one of BioWin’s strategic themes - #biopharma or #healthtech - then you may be eligible for funding. https://t.co/Eq0PnRuTXp
One more step for AbolerIS Pharma! The biotech has just dosed the first participants in a Phase 1 trial for ABO21009, a first-in-class anti-CD45RC monoclonal antibody for rheumatoid arthritis. https://t.co/MzHR0iYfTY
@CuriumPharma, a nuclear medicine company, has acquired Nucleis, a specialist in GMP manufacturing and distribution of PET radiopharmaceutical drugs.
https://t.co/MGPZ7sOz5b